In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy

G. Metro, Z. Zheng, A. Fabi, M. Schell, B. Antoniani, M. Mottolese, A. N. Monteiro, P. Vici, S. Lara Rivera, D. Boulware, F. Cognetti, G. Bepler

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-smallcell lung cancer and pancreatic cancer. We investigated the protein levels of RRM1 and two other DNA repair enzymes, ERCC1 and BRCA1, in 55 metastatic breast cancer (MBC) patients undergoing gemcitabine-based chemotherapy. With automated in situ protein quantification (AQUA v1.6), the average scores for RRM1, ERCC1, and BRCA1 ranged from 245.6.-2774.1, 74.0-410.3, and 54.4-1833.1, respectively. They were significantly associated with each other (Spearman's rho ≥ .36; p ≤ .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC.

Original languageEnglish
Pages (from-to)172-180
Number of pages9
JournalCancer Investigation
Volume28
Issue number2
DOIs
Publication statusPublished - 2010

Fingerprint

gemcitabine
Breast Neoplasms
DNA Repair Enzymes
Ribonucleotide Reductases
Drug Therapy
Pancreatic Neoplasms
Lung Neoplasms
Proteins

Keywords

  • BRCA1
  • ERCC1
  • Gemcitabine
  • Metastatic breast cancer
  • RRM1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. / Metro, G.; Zheng, Z.; Fabi, A.; Schell, M.; Antoniani, B.; Mottolese, M.; Monteiro, A. N.; Vici, P.; Rivera, S. Lara; Boulware, D.; Cognetti, F.; Bepler, G.

In: Cancer Investigation, Vol. 28, No. 2, 2010, p. 172-180.

Research output: Contribution to journalArticle

Metro, G. ; Zheng, Z. ; Fabi, A. ; Schell, M. ; Antoniani, B. ; Mottolese, M. ; Monteiro, A. N. ; Vici, P. ; Rivera, S. Lara ; Boulware, D. ; Cognetti, F. ; Bepler, G. / In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. In: Cancer Investigation. 2010 ; Vol. 28, No. 2. pp. 172-180.
@article{8a1369f0f4974183bdab2334a6563919,
title = "In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy",
abstract = "Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-smallcell lung cancer and pancreatic cancer. We investigated the protein levels of RRM1 and two other DNA repair enzymes, ERCC1 and BRCA1, in 55 metastatic breast cancer (MBC) patients undergoing gemcitabine-based chemotherapy. With automated in situ protein quantification (AQUA v1.6), the average scores for RRM1, ERCC1, and BRCA1 ranged from 245.6.-2774.1, 74.0-410.3, and 54.4-1833.1, respectively. They were significantly associated with each other (Spearman's rho ≥ .36; p ≤ .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC.",
keywords = "BRCA1, ERCC1, Gemcitabine, Metastatic breast cancer, RRM1",
author = "G. Metro and Z. Zheng and A. Fabi and M. Schell and B. Antoniani and M. Mottolese and Monteiro, {A. N.} and P. Vici and Rivera, {S. Lara} and D. Boulware and F. Cognetti and G. Bepler",
year = "2010",
doi = "10.3109/07357900903095722",
language = "English",
volume = "28",
pages = "172--180",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy

AU - Metro, G.

AU - Zheng, Z.

AU - Fabi, A.

AU - Schell, M.

AU - Antoniani, B.

AU - Mottolese, M.

AU - Monteiro, A. N.

AU - Vici, P.

AU - Rivera, S. Lara

AU - Boulware, D.

AU - Cognetti, F.

AU - Bepler, G.

PY - 2010

Y1 - 2010

N2 - Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-smallcell lung cancer and pancreatic cancer. We investigated the protein levels of RRM1 and two other DNA repair enzymes, ERCC1 and BRCA1, in 55 metastatic breast cancer (MBC) patients undergoing gemcitabine-based chemotherapy. With automated in situ protein quantification (AQUA v1.6), the average scores for RRM1, ERCC1, and BRCA1 ranged from 245.6.-2774.1, 74.0-410.3, and 54.4-1833.1, respectively. They were significantly associated with each other (Spearman's rho ≥ .36; p ≤ .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC.

AB - Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-smallcell lung cancer and pancreatic cancer. We investigated the protein levels of RRM1 and two other DNA repair enzymes, ERCC1 and BRCA1, in 55 metastatic breast cancer (MBC) patients undergoing gemcitabine-based chemotherapy. With automated in situ protein quantification (AQUA v1.6), the average scores for RRM1, ERCC1, and BRCA1 ranged from 245.6.-2774.1, 74.0-410.3, and 54.4-1833.1, respectively. They were significantly associated with each other (Spearman's rho ≥ .36; p ≤ .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC.

KW - BRCA1

KW - ERCC1

KW - Gemcitabine

KW - Metastatic breast cancer

KW - RRM1

UR - http://www.scopus.com/inward/record.url?scp=77149164753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149164753&partnerID=8YFLogxK

U2 - 10.3109/07357900903095722

DO - 10.3109/07357900903095722

M3 - Article

C2 - 19968494

AN - SCOPUS:77149164753

VL - 28

SP - 172

EP - 180

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -